The use of non-viral gene vectors for bioactive poly-(D,L-lactide) implant surfaces in bone tissue engineering

European Cells and Materials

Volumn 23, Issue , 2012, Pages 441-448

  Reckhenrich, Ann K ^a   Koch, Christian ^a   Egaña, José T ^a,b   Plank, Christian ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

Bioactive surface; Bone regeneration; Controlled drug release; Implant integrity; Nanobiotechnology; Non viral gene therapy

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; OSTEOCALCIN; OSTEOPONTIN; POLYCAPROLACTONE; POLYLACTIDE; TISSUE SCAFFOLD;

ANIMAL CELL; ARTICLE; BIODEGRADABLE IMPLANT; BONE REGENERATION; CELL ADHESION; CELL TRANSDIFFERENTIATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; COPOLYMER PROTECTED GENE VECTOR; ENZYME ACTIVITY; GENE ACTIVATION; GENE VECTOR; IN VITRO STUDY; MOUSE; MYOBLAST; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OSTEOBLAST; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN SECRETION; SURFACE PROPERTY; TISSUE ENGINEERING;

EID: 84865547513     PISSN: 14732262     EISSN: None     Source Type: Journal    
DOI: 10.22203/eCM.v023a34     Document Type: Article

References (40)

1. Barnes GL, Kostenuik PJ, Gerstenfeld LC, Einhorn TA (1999) Growth factor regulation of fracture repair. J Bone Miner Res 14: 1805-1815.
2. Bessa PC, Casal M, Reis RL (2008a) Bone morphogenetic proteins in tissue engineering: the road from the laboratory to the clinic, part I (basic concepts). J Tissue Eng Regen Med 2: 1-13.
3. Bessa PC, Casal M, Reis RL (2008b) Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery). J Tissue Eng Regen Med 2: 81-96.
4. Bilic R, Simic P, Jelic M, Stern-Padovan R, Dodig D, van Meerdervoort HP, Martinovic S, Ivankovic D, Pecina M, Vukicevic S (2006) Osteogenic protein-1 (BMP-7) accelerates healing of scaphoid non-union with proximal pole sclerosis. Int Orthop 30: 128-134.
5. Bueno EM, Glowacki J (2009) Cell-free and cell-based approaches for bone regeneration. Nat Rev Rheumatol 5: 685-697.
6. Causa F, Netti PA, Ambrosio L, Ciapetti G, Baldini N, Pagani S, Martini D, Giunti A (2006) Poly-epsilon-caprolactone/hydroxyapatite composites for bone regeneration: in vitro characterization and human osteoblast response. J Biomed Mater Res A 76: 151-162.
7. Chen D, Zhao M, Mundy GR (2004) Bone morphogenetic proteins. Growth Factors 22: 233-241.
8. Dimar JR, Glassman SD, Burkus KJ, Carreon LY (2006) Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/ compression resistant matrix versus iliac crest bone graft. Spine 31: 2534-2539; discussion 2540.
9. Donaldson LJ, Reckless IP, Scholes S, Mindell JS, Shelton NJ (2008) The epidemiology of fractures in England. J Epidemiol Community Health 62: 174-180.
10. Finsinger D, Remy JS, Erbacher P, Koch C, Plank C (2000) Protective copolymers for nonviral gene vectors: synthesis, vector characterization and application in gene delivery. Gene Ther 7: 1183-1192.
11. Garrison KR, Shemilt I, Donell S, Ryder JJ, Mugford M, Harvey I, Song F, Alt V (2010) Bone morphogenetic protein (BMP) for fracture healing in adults. Cochrane Database Syst Rev 6: CD006950.
12. Gelse K, von der Mark K, Aigner T, Park J, Schneider H (2003) Articular cartilage repair by gene therapy using growth factor-producing mesenchymal cells. Arthritis Rheum 48: 430-441.
13. Giannoudis PV, Dinopoulos H, Tsiridis E (2005) Bone substitutes: an update. Injury 36 Suppl 3: S20-27.
14. Gunatillake PA, Adhikari R (2003) Biodegradable synthetic polymers for tissue engineering. Eur Cell Mater 5: 1-16; discussion 16.
15. Honig D, DeRouchey J, Jungmann R, Koch C, Plank C, Radler JO (2010) Biophysical characterization of copolymer-protected gene vectors. Biomacromolecules 11: 1802-1809.
16. Hutmacher DW, Schantz T, Zein I, Ng KW, Teoh SH, Tan KC (2001) Mechanical properties and cell cultural response of polycaprolactone scaffolds designed and fabricated via fused deposition modeling. J Biomed Mater Res 55: 203-216.
17. Jones AL, Bucholz RW, Bosse MJ, Mirza SK, Lyon TR, Webb LX, Pollak AN, Golden JD, Valentin-Opran A (2006) Recombinant human BMP-2 and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures with cortical defects. A randomized, controlled trial. J Bone Joint Surg Am 88: 1431-1441.
18. Kanakaris NK, Calori GM, Verdonk R, Burssens P, De Biase P, Capanna R, Vangosa LB, Cherubino P, Baldo F, Ristiniemi J, Kontakis G, Giannoudis PV (2008) Application of BMP-7 to tibial non-unions: a 3-year multicenter experience. Injury 39 Suppl 2: S83-S90.
19. Kanczler JM, Oreffo RO (2008) Osteogenesis and angiogenesis: the potential for engineering bone. Eur Cell Mater 15: 100-114.
20. Kirker-Head CA (2000) Potential applications and delivery strategies for bone morphogenetic proteins. Adv Drug Deliv Rev 43: 65-92.
21. Kolk A, Haczek C, Koch C, Vogt S, Kullmer M, Pautke C, Deppe H, Plank C (2011) A strategy to establish a gene-activated matrix on titanium using gene vectors protected in a polylactide coating. Biomaterials 32: 6850-6859.
22. Lee SH, Shin H (2007) Matrices and scaffolds for delivery of bioactive molecules in bone and cartilage tissue engineering. Adv Drug Deliv Rev 59: 339-359.
23. Margolis DJ, Crombleholme T, Herlyn M (2000) Clinical protocol: Phase I trial to evaluate the safety of H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer. Wound Repair Regen 8: 480-493.
24. Margolis DJ, Cromblehome T, Herlyn M, Cross P, Weinberg L, Filip J, Propert K (2004) Clinical protocol. Phase I trial to evaluate the safety of H5.020CMV.PDGF-b and limb compression bandage for the treatment of venous leg ulcer: trial A. Hum Gene Ther 15: 1003-1019.
25. Marks SC, Jr., Popoff SN (1988) Bone cell biology: the regulation of development, structure, and function in the skeleton. Am J Anat 183: 1-44.
26. Mavrogenis AF, Dimitriou R, Parvizi J, Babis GC (2009) Biology of implant osseointegration. J Musculoskelet Neuronal Interact 9: 61-71.
27. Middleton JC, Tipton AJ (2000) Synthetic biodegradable polymers as orthopedic devices. Biomaterials 21: 2335-2346.
28. Mulder G, Tallis AJ, Marshall VT, Mozingo D, Phillips L, Pierce GF, Chandler LA, Sosnowski BK (2009) Treatment of nonhealing diabetic foot ulcers with a platelet-derived growth factor gene-activated matrix (GAM501): results of a phase 1/2 trial. Wound Repair Regen 17: 772-779.
29. Nakagawa T, Sugiyama T, Kamei T, Murata T, Tagawa T (2001) An immuno-light- and electron-microscopic study of the expression of bone morphogenetic protein-2 during the process of ectopic bone formation in the rat. Arch Oral Biol 46: 403-411.
30. Okubo Y, Bessho K, Fujimura K, Konishi Y, Kusumoto K, Ogawa Y, Iizuka T (2000) Osteoinduction by recombinant human bone morphogenetic protein-2 at intramuscular, intermuscular, subcutaneous and intrafatty sites. Int J Oral Maxillofac Surg 29: 62-66.
31. Pelttari K, Winter A, Steck E, Goetzke K, Hennig T, Ochs BG, Aigner T, Richter W (2006) Premature induction of hypertrophy during in vitro chondrogenesis of human mesenchymal stem cells correlates with calcification and vascular invasion after ectopic transplantation in SCID mice. Arthritis Rheum 54: 3254-3266.
32. Rai B, Teoh SH, Hutmacher DW, Cao T, Ho KH (2005) Novel PCL-based honeycomb scaffolds as drug delivery systems for rhBMP-2. Biomaterials 26: 3739-3748.
33. Schmidmaier G, Wildemann B, Cromme F, Kandziora F, Haas NP, Raschke M (2002) Bone morphogenetic protein-2 coating of titanium implants increases biomechanical strength and accelerates bone remodeling in fracture treatment: a biomechanical and histological study in rats. Bone 30: 816-822.
34. Steinhardt Y, Aslan H, Regev E, Zilberman Y, Kallai I, Gazit D, Gazit Z (2008) Maxillofacial-derived stem cells regenerate critical mandibular bone defect. Tissue Eng Part A 14: 1763-1773.
35. Tsuji K, Bandyopadhyay A, Harfe BD, Cox K, Kakar S, Gerstenfeld L, Einhorn T, Tabin CJ, Rosen V (2006) BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet 38: 1424-1429.
36. Urist MR (1965) Bone: formation by autoinduction. Science 150: 893-899.
37. Valentin-Opran A, Wozney J, Csimma C, Lilly L, Riedel GE (2002) Clinical evaluation of recombinant human bone morphogenetic protein-2. Clin Orthop Relat Res 395: 110-120.
38. Wildemann B, Kandziora F, Krummrey G, Palasdies N, Haas NP, Raschke M, Schmidmaier G (2004) Local and controlled release of growth factors (combination of IGF-I and TGF-beta I, and BMP-2 alone) from a polylactide coating of titanium implants does not lead to ectopic bone formation in sheep muscle. J Control Release 95: 249-256.
39. Wintermantel E, Ha SW (2009) Medizintechnik: Life Science Engineering. Springer-Verlag GmbH, Berlin, pp 265-270.
40. Zhang X, Godbey WT (2006) Viral vectors for gene delivery in tissue engineering. Adv Drug Deliv Rev 58: 515-534.